This article was originally published in The Gray Sheet
Percutaneous transluminal coronary angioplasty guidewire system "designed to facilitate the exchange of over-the-wire PTCA catheters" will be launched within "the next few months," the company says. The system, comprised of the EnTre II guidewire and the Magnet exchange device, uses "magnets to maintain the position of the guidewire" during removal. The system was cleared for marketing by FDA on June 25.
You may also be interested in...
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.
Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.